drugset
drugset / Trial / NCT00659074

Bioavailability Study of Ondansetron 24 mg Orally Disintegrating Tablets Under Fasting Conditions

NCT00659074 ↗

Phase 1 Completed 24 enrolled Par Pharmaceutical, Inc. Algorithme Pharma Inc · collab
RandomizedFactorialOpen-label

Summary

Single-dose cross over comparative bioavailability of Ondansetron 24 mg oDT and Zofran 24 mg ODT

Timeline

Start
2003-10
Primary completion
2004-01
Completion
2004-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ondansetron Other / unclassified 24 mg Oral

Indications

No indication recorded.